Table 1 Single-agent trials of IFNα: a historical overview
From: Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
Trial | IFNα dose | IFNα form | n | CHR rate (%) | Median survival (months) |
|---|---|---|---|---|---|
Talpaz et al.6 | 9 MU | Partially pure | 7 | 71 | |
Talpaz et al.7 | 3–9 MU | Partially pure | 51 | 71 | |
Alimena et al.11a | 2–5 MU/m2 | rIFNα-2b | 105 | 59 | |
Talpaz et al.8 | 3–9 MU (partially pure) or 5 MU/m2 (rIFNα-2a) | Partially pure or rIFNα-2a | 96 | 73 | 62 |
Niederle et al.13 | 4 MU/m2 IFNα | rIFNα-2b | 48 | 46 | |
Ozer et al.10 | 5 MU/m2 | rIFNα-2b | 107 | 22 | 66 |
Thaler et al.12 | 3.5 MU | rIFNα-2c | 80 | 39 | |
Hehlmann et al.15 | 5 MU/m2 | rIFNα-2a or rIFNα-2b | 133 | 31 | 66 |
Italian Cooperative Study Group on Chronic Myeloid Leukemia14 | 3–9 MU | rIFNα-2a | 218 | 45 (complete and partial) | 72 |
Allan et al.17 | 3–12 MU | Highly purified | 293 | 68 | 61 |
Ohnishi et al.16 | 3–9 MU | rIFNα-2a | 80 | 39 |
